雷珠单抗与傲迪适注射治疗对伴ME的RVO患者黄斑区血流的影响  

The effect of ranibizumab and aodishi injection on macular blood flow in RVO patients with me

作　　者：周冠芳 蒋劲[2] 郑青青[2] 沈婷[2] 洪朝阳[2] Zhou Guanfang

机构地区：[1]蚌埠医学院研究生院,233000 [2]浙江省人民医院眼科,310014

出　　处：《浙江临床医学》2021年第4期486-489,共4页Zhejiang Clinical Medical Journal

基　　金：国家卫生计生委科学研究基金(WKJ-ZJ-1813);浙江省中医药管理局科研基金项目(2018ZA014);浙江省卫生健康面上项目(2021KY469)。

摘　　要：目的观察视网膜静脉阻塞(RVO)伴黄斑水肿(ME)患者玻璃体腔注射雷珠单抗或傲迪适治疗前后,黄斑区视网膜、脉络膜血流变化情况,以评估两种药物临床治疗效果.方法纳入2019年11月至2020年12月在浙江省人民医院就诊的RVO伴发ME患者110例.随机分为雷珠单抗组和傲迪适组,雷珠单抗组60例,玻璃体腔注射雷珠单抗;傲迪适组50例,玻璃体腔注射傲迪适;另同期选取眼部屈光介质清且无其他眼部疾病(轻度白内障除外)的正常人40例,作为对照组.于玻璃体腔内注射药物治疗前后行OCTA血流成像技术测量患者视网膜、脉络膜MVD以及FAZ面积.结果RVO患者玻璃体腔注射雷珠单抗或傲迪适后,黄斑区各层MVD较治疗前均有增加,且有统计学差异(P<0.05);浅层FAZ面积较治疗前减小且有差异(P<0.05).两种药物治疗后比较,雷珠单抗组、傲迪适组DVC层MVD分别为36.08%±1.04%、38.63%±1.63%,只有DVC层MVD增加有统计学差异(P<0.05).结论RVO伴黄斑水肿患者相比正常人,黄斑区视网膜脉络膜各层的MVD偏低;RVO伴ME患者注射雷珠单抗与注射傲迪适对比,只有DVC层MVD增加是有差异的,且傲迪适组增加幅度更大.Objeetive To observe the changes of retinal and choroidal blood flow in macular area in patients with reinal vein occlusion macular edema ( RVO- ME ) after intraocular injections of Lucentis or Ozurdex,in order to evaluate the curative ffect. Methods A study was conductedin 110 eyes of patients with central retinal vein oclusion ( CRVO ) and branch retimal vein occlusion ( BRVO ) with ME in the Department of Ophthalmology,Zhejiang people's Hospital from November 2019 to December 2020.All patients were randomly treated with intavitreous injecion of Lucentis ( Lucentis group) or Ozurdex ( Ozurdex group),60 eyes in Lucentis group and 50 eyes in Ozurdex group. At the same time, and 40 normal people with clear refractive medium and no other eye diseases ( except mild cataract ) were selected as the control group.The OCTA was used to measure the CMT, MVD of macular retina and choroid, and FAZ area before and afer intravitreal injection. Results After intravitreous injection of Lucentis or Ozurdex in RVO patients, MVD of macular area in RVO patients increased significantly ( P<0.05),and FAZ area of superficial layer decreased significantly ( P<0.05 ).The MVD of DVC layer in ranibizumab group and aodishi group were 36.08%±1.04% and 38.63%±1.63% respectively, and only the increase of MVD in the DVC layer had significant diference ( P<0.05 ) . Conclusion The MVD in macular rerina and choroidal layers of RVO patients with ME is lower than that of normal subjects, and compared with the injection of Lncentis in RVO patients with ME,only the increase of MVD in DVC layer is significant., and the increase in Ozurdex group is greater.

关 键 词：视网膜静脉阻塞 黄斑水肿 中心凹无血管区面积 黄斑区血管密度 

分 类 号：R73[医药卫生—肿瘤]